ViiV adds to case for two-drug HIV regimen

In its attempts to show the effectiveness of using two drug combinations in HIV, ViiV Healthcare has added more data to its evidence base.

The company, which is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), has presented findings from the Phase III GEMINI 1 and 2 studies at the International AIDS conference in Amsterdam.

This data assessed the safety and efficacy of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine, in treatment-naïve, HIV-1 infected adults with baseline viral loads up to 500,000 copies per millilitre.